Karyopharm Therapeutics Inc. (NASDAQ: KPTI)
$0.98
-0.0249 ( -2.49% ) 409.5K
Karyopharm Therapeutics Inc is a commercial-stage pharmaceutical company pioneering novel cancer therapies and dedicated to the discovery, development, and commercialization of drugs directed against nuclear export for the treatment of cancer and other diseases. XPOVIO (selinexor), is approved in the U.S. in multiple hematologic malignancy indications, including in combination with Velcade (bortezomib) and dexamethasone for the treatment of adult patients with multiple myeloma after at least one prior therapy, in combination with dexamethasone for the treatment of adult patients with heavily pretreated multiple myeloma and as a monotherapy for the treatment of adult patients with relapsed or refractory diffuse large B-cell lymphoma. The company derives its revenue from United States.
Market Data
Open
$0.98
Previous close
$1.00
Volume
409.5K
Market cap
$121.18M
Day range
$0.96 - $1.04
52 week range
$0.62 - $1.95
SEC Fillings
Form Type | Description | Pages | Date |
---|---|---|---|
4 | Insider transactions | 1 | Jul 09, 2024 |
4 | Insider transactions | 1 | Jun 07, 2024 |
4 | Insider transactions | 1 | Jun 06, 2024 |
4 | Insider transactions | 1 | Jun 06, 2024 |
4 | Insider transactions | 1 | Jun 04, 2024 |
8-k | 8K-related | 13 | May 31, 2024 |
4 | Insider transactions | 1 | May 30, 2024 |
4 | Insider transactions | 1 | May 30, 2024 |
4 | Insider transactions | 1 | May 30, 2024 |
4 | Insider transactions | 1 | May 30, 2024 |